Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
作者信息
Alonso-Padilla Julio, Abril Marcelo, Alarcón de Noya Belkisyolé, Almeida Igor C, Angheben Andrea, Araujo Jorge Tania, Chatelain Eric, Esteva Monica, Gascón Joaquim, Grijalva Mario J, Guhl Felipe, Hasslocher-Moreno Alejandro Marcel, López Manuel Carlos, Luquetti Alejandro, Noya Oscar, Pinazo María Jesús, Ramsey Janine M, Ribeiro Isabela, Ruiz Andres Mariano, Schijman Alejandro G, Sosa-Estani Sergio, Thomas M Carmen, Torrico Faustino, Zrein Maan, Picado Albert
机构信息
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-University of Barcelona, Barcelona, Spain.
Fundación Mundo Sano, Buenos Aires, Argentina.
出版信息
PLoS Negl Trop Dis. 2020 Apr 23;14(4):e0008035. doi: 10.1371/journal.pntd.0008035. eCollection 2020 Apr.
Abstract
摘要
相似文献
1
Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.恰加斯病患者治疗疗效早期评估检测的目标产品概况：专家共识
PLoS Negl Trop Dis. 2020 Apr 23;14(4):e0008035. doi: 10.1371/journal.pntd.0008035. eCollection 2020 Apr.
2
Should trypanocidal therapy be used to treat patients in the chronic phase of Chagas disease?是否应该使用杀锥虫疗法来治疗恰加斯病慢性期的患者？
Medwave. 2015 Oct 26;15 Suppl 2:e6291. doi: 10.5867/medwave.2015.6291.
3
[New insights into pathophysiology and treatment in Chagas-Mazza disease].[恰加斯-马扎病病理生理学与治疗的新见解]
Rev Fac Cien Med Univ Nac Cordoba. 2011;68(4):154-63.
4
The urgent need to develop new drugs and tools for the treatment of Chagas disease.开发治疗恰加斯病的新药和工具的迫切需求。
Expert Rev Anti Infect Ther. 2011 Jan;9(1):5-7. doi: 10.1586/eri.10.144.
5
Parasitological cure of Chagas disease: is it possible? Is it relevant?恰加斯病的寄生虫学治愈：是否可行？是否重要？
Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:349-55. doi: 10.1590/s0074-02761999000700068.
6
Criteria of Chagas disease cure.恰加斯病治愈标准。
Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:331-5. doi: 10.1590/s0074-02761999000700064.
7
[Guiding the etiological treatment of Chagas disease].[指导恰加斯病的病因治疗]
Medicina (B Aires). 2015;75(4):270-1.
8
[The chemotherapy of infections produced by Trypanosoma cruzi].[克氏锥虫所致感染的化学疗法]
Salud Publica Mex. 1997 Sep-Oct;39(5):463-71.
9
In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease.环钯配合物 7a 的体外和体内杀锥虫效果，一种治疗恰加斯病的候选药物。
Antimicrob Agents Chemother. 2010 Aug;54(8):3318-25. doi: 10.1128/AAC.00323-10. Epub 2010 May 17.
10
[Treatment of chronic Chagas' disease. Is the etiological treatment effective?].[慢性恰加斯病的治疗。病因治疗是否有效？]
Arq Bras Cardiol. 1998 Oct;71(4):643-6.
引用本文的文献
1
Reporter genes and transgenic (Kinetoplastida, Trypanosomatidae): applications for screening new drugs against Chagas disease.报告基因与转基因（动质体目，锥虫科）：用于筛选抗恰加斯病新药的应用
Front Med (Lausanne). 2025 May 20;12:1591148. doi: 10.3389/fmed.2025.1591148. eCollection 2025.
2
Chagas disease treatment efficacy markers: experiences from a Phase III study with nifurtimox in children.恰加斯病治疗疗效标志物：硝呋替莫治疗儿童的III期研究经验
Front Parasitol. 2023 Sep 22;2:1229467. doi: 10.3389/fpara.2023.1229467. eCollection 2023.
3
Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.抗寄生虫治疗对慢性恰加斯病心血管结局的影响。一项系统评价和荟萃分析。
EClinicalMedicine. 2024 Dec 24;79:102972. doi: 10.1016/j.eclinm.2024.102972. eCollection 2025 Jan.
4
Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.使用血清学多重免疫测定法对恰加斯病患者治疗后抗体下降情况进行早期评估。
Nat Commun. 2024 Dec 3;15(1):10530. doi: 10.1038/s41467-024-54910-x.
5
Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection.脂质丰度的变化与慢性克氏锥虫感染的疾病进展和治疗反应有关。
Parasit Vectors. 2024 Nov 9;17(1):459. doi: 10.1186/s13071-024-06548-3.
6
Diversity of Chagas disease diagnostic antigens: Successes and limitations.克氏锥虫病诊断抗原的多样性：成功与局限。
PLoS Negl Trop Dis. 2024 Oct 1;18(10):e0012512. doi: 10.1371/journal.pntd.0012512. eCollection 2024 Oct.
7
A Multi-Epitope Protein for High-Performance Serodiagnosis of Chronic Chagas Disease in ELISA and Lateral Flow Platforms.用于 ELISA 和横向流动平台的高灵敏度慢性恰加斯病血清学诊断的多表位蛋白。
Int J Mol Sci. 2024 Sep 11;25(18):9811. doi: 10.3390/ijms25189811.
8
Consensus-driven target product profiles for curative sickle cell disease gene therapies.针对治愈性镰状细胞病基因疗法的共识驱动型目标产品概况。
Mol Ther Methods Clin Dev. 2024 Jun 22;32(3):101287. doi: 10.1016/j.omtm.2024.101287. eCollection 2024 Sep 12.
9
Facilitating the use of the target product profile in academic research: a systematic review.促进目标产品特性在学术研究中的使用：系统评价。
J Transl Med. 2024 Jul 29;22(1):693. doi: 10.1186/s12967-024-05476-1.
10
An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.α-半乳糖抗原替代标志物用于评价感染克氏锥虫儿童的治疗效果：一项回顾性队列研究。
PLoS Negl Trop Dis. 2024 Jan 18;18(1):e0011910. doi: 10.1371/journal.pntd.0011910. eCollection 2024 Jan.
本文引用的文献
1
A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.一种寄生虫生物标志物集，用于评估慢性无症状感染克氏锥虫病患者的苯硝唑治疗效果。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.02436-18. Print 2019 Oct.
2
Rapid immunochromatographic tests for the diagnosis of chronic Chagas disease in at-risk populations: A systematic review and meta-analysis.快速免疫层析试验诊断高危人群慢性恰加斯病：系统评价和荟萃分析。
PLoS Negl Trop Dis. 2019 May 31;13(5):e0007271. doi: 10.1371/journal.pntd.0007271. eCollection 2019 May.
3
Target Product Profile for a point-of-care diagnostic test for dermal leishmaniases.皮肤利什曼病即时检测诊断测试的目标产品概况。
Parasite Epidemiol Control. 2019 Mar 7;5:e00103. doi: 10.1016/j.parepi.2019.e00103. eCollection 2019 May.
4
Characterization of digestive disorders of patients with chronic Chagas disease in Cochabamba, Bolivia.玻利维亚科恰班巴慢性恰加斯病患者消化系统疾病的特征
Heliyon. 2019 Feb 7;5(2):e01206. doi: 10.1016/j.heliyon.2019.e01206. eCollection 2019 Feb.
5
Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America.在拉丁美洲，提高对恰加斯病患者的诊断和治疗机会的策略。
Expert Rev Anti Infect Ther. 2019 Mar;17(3):145-157. doi: 10.1080/14787210.2019.1577731. Epub 2019 Feb 13.
6
Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease.用于慢性恰加斯病患者治疗监测的连续血样采集和 PCR 重复检测的实用性。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01191-18. Print 2019 Feb.
7
Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.贝那唑嗪在恰加斯病中的有益作用：NIH SaMi-Trop 队列研究。
PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006814. doi: 10.1371/journal.pntd.0006814. eCollection 2018 Nov.
8
A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.一种新型抗体替代生物标志物，用于监测感染克氏锥虫的患者寄生虫的持续存在。
PLoS Negl Trop Dis. 2018 Feb 9;12(2):e0006226. doi: 10.1371/journal.pntd.0006226. eCollection 2018 Feb.
9
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.使用苯硝唑和三种 E1224 给药方案治疗成人慢性不定型恰加斯病：概念验证、随机、安慰剂对照试验。
Lancet Infect Dis. 2018 Apr;18(4):419-430. doi: 10.1016/S1473-3099(17)30538-8. Epub 2018 Jan 16.
10
What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment.预期和时间：苯达唑治疗慢性恰加斯病的毒性。
J Antimicrob Chemother. 2018 Apr 1;73(4):1060-1067. doi: 10.1093/jac/dkx516.
Zotero 插件